Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
View Scopus Profile
Ori Tal
Doctor
Lecturer
,
Faculty of Medicine
,
Obstetrics & Gynecology
2019
2025
Research activity per year
Overview
Fingerprint
Network
Research output
(17)
Similar Profiles
(10)
Fingerprint
Dive into the research topics where Ori Tal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Krukenberg Tumor
100%
Ovarian Cancer
62%
Combination Therapy
58%
Uterine Cancer
58%
Prognostic Factor
46%
Recurrent Disease
43%
Diseases
41%
First Trimester Pregnancy
38%
Retrospective Cohort Study
36%
Platelet
32%
Ovarian Tumor
26%
CA-125
25%
Dilation and Curettage
22%
Debulking
22%
Gynecological Oncology
19%
Rare Disease
19%
In Vitro Fertilisation
19%
Analgesia
19%
Sentinel Lymph Node
19%
Perineum Injury
19%
Spontaneous Abortion
19%
Coagulation Testing
19%
Meconium
19%
Randomized Controlled Trial
19%
Thrombocytosis
19%
Menstrual Cycle
19%
Amnion Fluid
19%
Symptom Management
19%
Paraaortic Lymph Node
19%
Histopathology
19%
Pre-Eclampsia
19%
Body Mass Index
19%
Caloric Restriction
19%
Genomic Signature
19%
Lymphocyte
19%
Cytoreductive Surgery
19%
Minimal Residual Disease
19%
Debulking Surgery
19%
Crown Rump Length
19%
Gestational Age
19%
Overall Survival
18%
Laparoscopic Surgery
17%
Placebo
16%
Symptomatic Treatment
14%
Bupivacaine
12%
Malignant Neoplasm
12%
Hysteroscopy
12%
Indocyanine Green
11%
Misoprostol
10%
Gestational Sac
10%
Keyphrases
Epithelial Ovarian Cancer
79%
Medical Treatment
58%
Endometrial Cancer
58%
Adverse Pregnancy Outcomes
38%
Early Pregnancy Loss
38%
Surgical Intervention
37%
Retrospective Cohort Study
35%
Ultrasound
32%
Ovarian Cancer Patients
31%
Curettage
29%
Overall Survival
25%
Israeli
24%
Treatment Outcome
24%
Adverse Neonatal Outcome
22%
Cancer Patients
22%
Treatment Failure
22%
Prognostic Factors
21%
In Vitro Fertilization
19%
Vaginal Examination
19%
End-of-life Symptom Management
19%
Meconium Staining
19%
Lymph Node Recurrence
19%
Meconium-stained Amniotic Fluid
19%
Retroperitoneal Lymph Node
19%
Perineal Trauma
19%
Cancer Prognostics
19%
Coagulation Testing
19%
Postmenopausal Patients
19%
Low-grade Serous Ovarian Cancer
19%
Intraperitoneal Local Anaesthetic
19%
Intraperitoneal Analgesia
19%
Spontaneous Preterm Birth (sPTB)
19%
Amniotic Fluid
19%
Borderline Ovarian Tumor
19%
Preeclampsia
19%
Sentinel Lymph Node Mapping
19%
Thrombocytosis
19%
Age Disparity
19%
Prognostic Significance
19%
Gynecologic Oncology Group
19%
Group Studies
19%
Placebo
19%
Placental Pathology
19%
Abnormal Coagulation
19%
Anatomic
19%
Randomized Controlled Trial
19%
Trocar Site
19%
Rare Diseases
19%
Body Mass Index
19%
Gestational Age
19%
